of osteocalcin that is similar to radioimmunoassay but uses acridinium-ester-labeled antigen instead of 125, labeled osteocalcin; a second antibody immobilized on plastic beads is used to separate free and bound fractions. There , and incubated at room temperature on an orbital shaker at 100 rpm for an additional 2.5 h. We used glycine for blocking because the larger-Me bovine serum albumin had a tendency to remove antibody from the beads. Finally Intraassay variation was 6% (8.0 ± 0.48 gfL; n = 40 determinations).
All these quality-control studies were done with a single preparation of acridinium-ester-labeled osteocalcin within 6 months. The percentage of binding of the labeled osteocalcun was between 45% and 50% of the total counts; after 6 months, the percentage of binding decreased to 35%. We estimated the stability of acridinium-ester-labeled osteocalcm to be about 6 months, about the same length of "shell-life" as other acridinium ester labels (13).
The new CIA recognized intact osteocalcin and the 1ow-M fragment of osteocalcin after separation of serum by gel filtration.. It also detected the decrease of intact osteocalcin and the osteocalcin fragment after a 24-h infusion of PTH. The relative peak area after PTH infusion decreased from 640 to 342 arbitrary area units, a decrease of 47% (Figure 1 ). PTH but showed good correlation with the concentra-
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______________________________ tions of C-terminal PTH (r = 0.83, P = 0.0001) ( Table 7) .
After gel-column separation, we found an increased peak for intact osteocalcin in the plasma of patients osteocalcin. Figure 3 . cancer, and the patient with parathyroid carcinoma. All Women by CIA (r = -0.41 and -0.360, respectively, both P <0.05); by RIA, however, Using a nonradioactive acridinium ester tracer increased the shelf-life of tracer without losing assay sensitivity and also, as an environmental concern, reduced the amount of radioactive waste generated from a clinical laboratory. Fig. 1, pethapsovershadowed creased amount of intact osteocalcin during gel-column separation (Figure 3) .
An example is shown in
Another laboratory demonstrated that a monoclonal RIA recognized both intact osteocalcin and the small fragment of osteocalcin. The results of monoclonal RIA were 1.5 times greater than the results of the RIA with polyclonal R102, because the latter RIA could not detect the small fragment of osteocalcin (11). Our current finding that CIA results were 1.3 times greater than RIA results obtained with the same antiserum R102 might be for the same reason; i.e., our results were higher than RIA because our assay also recognized the small fragment.
We could not explain the good correlation of circulating osteocalcin values with C-terminal PTH values (r = 0.83, P = 0.0001) combined with a poor correlation with the biologically active intact PTH ( In conclusion, we achieved two goals: (a) acridinium ester can be used to prepare CIAs, and the performance of the new assay compares very well with the established RIA that uses antiserum R102; (b) the new CIA appears to be as useful as RIA (R102) for determining bone formation and for monitoring bone turnover rate and thus may reduce use of the invasive bone histomorphometry test.
